RxDoctor Payments Data

Rory Allar, MD

Ophthalmology · Spokane, WANPI 1326272691

Payments from drug & device makers

$1,543in general payments, 2019–2025

Across 31 payments — averaging $49.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$667
  • AbbVie$297
  • Glaukos Corporation$200
  • Aerie Pharmaceuticals, Inc.$188
  • Alcon$88
  • Johnson & Johnson Surgical Vision, Inc.$46
  • plus $59 from 2 others

What the payments were for

  • Food & beverage$87657%
  • Ownership interest$66743%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,543 in reported general payments places this provider in the 60th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$449,440
Medicare patients
854
Services billed
3,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate102$51,530
RocklatanNetarsudil Mesylat/Latanoprost58$29,980
Latanoprost1,369$18,271
LumiganBimatoprost30$17,003
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat755$14,320
CombiganBrimonidine Tartrate/Timolol47$13,595
Prednisolone Acetate349$12,197
Brimonidine Tartrate366$9,813
SimbrinzaBrinzolamide/Brimonidine Tart24$8,825
Alphagan PBrimonidine Tartrate19$8,162
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol56$7,622
VyzultaLatanoprostene Bunod18$6,301
Ketorolac Tromethamine239$4,959
Travoprost17$4,742
Brinzolamide27$4,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$188$81,510160 claims
AbbVieLumigan, Combigan, Alphagan P$297$38,75996 claims
AlconSimbrinza$88$8,82524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →